Alembic Pharma's partner launches drug for depressive disorder
These are therapeutically equivalent to Pristiq of Pfizer03-03-2017
03-03-2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Birla Sun Life Asset Management Company Ltd15-02-2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Birla Sun Life Asset Management Company Ltd14-02-2017
Transcript of Tele conference call with analysts
Pfizer Ltd has submitted to BSE a copy of the transcript of the tele conference call with the analysts held on February 01, 2017, to discuss the Company's financial performance for the third quarter and nine months ended December 31, 2016.02-02-2017
Appointment of Director
Pfizer Ltd has informed BSE that the Board of Directors of the Company at its held Meeting on January 30, 2017, has appointed Mr. Ravi Prakash Bhagavathula as an Additional Director of the Company, designated as an Executive Director, Finance with effect from January 30, 2017 for a period of 5 years. The appointment of Mr. Ravi Prakash will be subject to the approval of shareholders at the forthcoming Annual General Meeting of the Company.30-01-2017
Schedule of Analyst Teleconference
Pfizer Ltd has informed BSE regarding "Schedule of Analyst Teleconference".30-01-2017
Results Press Release for December 31, 2016
Pfizer Ltd has informed BSE about : 1. Result Press Release for the period ended December 31, 201630-01-2017
Announces Q3 results (Standalone) & Limited Review Report (Standalone) for the Quarter ended December 31, 2016
Pfizer Ltd has announced the Unaudited Standalone results for the quarter ended December 31, 2016:The Company has posted a net profit of Rs. 623.70 million for the quarter ended December 31, 2016 as compared to Rs. 597.60 million for the quarter ended December 31, 2015. Total Income has decreased from Rs. 5509.60 million for the quarter ended December 31, 2015 to Rs. 5367.50 million for the quarter ended December 31, 2016.30-01-2017
Q3 results on Jan 30, 2017
Pfizer Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on January 30, 2017, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2016 (Q3).Further, the Trading Window for trading in the Equity shares of the Company will be closed from January 20, 2017 to February 01, 2017, both days inclusive.19-01-2017
Updates
Pfizer Ltd has informed BSE regarding "Granting of authority to the Company by AstraZeneca Pharma India Limited for certain rights in relation to identified injectable antibiotic products through a Delegation of Authority".18-01-2017